Product Development Pipeline

The NIH, CDC and FDA Intramural Research Programs are exceptionally innovative as exemplified by the many products currently on the market that benefit the public every day (see Product Showcase). There are over a thousand inventions from the Intramural Programs that are currently available for licensing to companies for commercial development (see Licensing Opportunities). Many inventions, however, have been licensed and are now in clinical development with the hope of eventually reaching the market. These are displayed in the Product Development Pipeline.

Phase I

Acute myocardial infarction, Peripheral neuropathy, Stroke

Category:
Therapeutic
IC:
NIDCR
Licensee:
RegeneRX Biopharmaceuticals
Product:
RGN-352

Various cancers

Category:
Therapeutic
IC:
NCI
Licensee:
Jennerex
Product:
JX-929

Stargardt disease (juvenile macular degeneration)

Category:
Therapeutic
IC:
NCI
Licensee:
Oxford Biomedica
Product:
StarGen™

Solid tumors and lymphoma

Category:
Therapeutic
IC:
NCI
Licensee:
CerRx
Product:
IV Fenretinide (4-HRP)

Parkinson's and Alzheimer's diseases

Category:
Therapeutic
IC:
NIA
Licensee:
QR Pharma/Raptor Pharmaceuticals
Product:
Posiphen® and BNC

H. pylori infections (gastritis, ulcers, carcinomas)

Category:
Therapeutic
IC:
NIAID
Licensee:
Sequella
Product:
SQ109

Phase II

Acute radiation syndrome

Category:
Therapeutic
IC:
NCI
Licensee:
Henry Jackson Foundation/Humanetics
Product:
BIO 300

Anemia associated with uterine fibroids

Category:
Therapeutic
IC:
NICHD
Licensee:
Repros Therapeutics
Product:
Proellex®

Wound healing (Epidermolysis bullosa, Pressure ulcers, Venous stasis ulcers)

Category:
Therapeutic
IC:
NIDCR
Licensee:
RegeneRX Biopharmaceuticals
Product:
RGN-137

Lung cancer

Category:
Therapeutic
IC:
NCI
Licensee:
Genprex
Product:
Oncoprex®
Category:
Therapeutic
IC:
NIAID
Licensee:
Transgene
Product:
TG-4010

Mesothelin-expressing cancer

Category:
Therapeutic
IC:
NCI
Licensee:
Morphotek
Product:
Amatuximab (MORab-009)

Solid tumors

Category:
Therapeutic
IC:
NCI
Licensee:
U3 Pharma/Daiichi Sankyo
Product:
Patritumab (U3-1287)

T cell lymphoma

Category:
Therapeutic
IC:
NIMH
Licensee:
Angimmune
Product:
Resimmune™

Tuberculosis

Category:
Therapeutic
IC:
NIAID
Licensee:
Sequella
Product:
SQ109

Cerebral vasospasm, Ischemia-reperfusion injury

Category:
Therapeutic
IC:
NHLBI
Licensee:
Hope Pharmaceuticals
Product:
Sodium nitrite injection

Rotavirus

Category:
Vaccine
IC:
NIAID
Licensee:
International Medica Foundation
Product:
RotaShield®

Dengue haemorrhagic fever

Category:
Vaccine
IC:
NIAID / CDC
Licensee:
Takeda Vaccines (Montana) Inc.
Product:
DENVax (TAK-003)

Phase III

Dengue haemorrhagic fever

Category:
Vaccine
IC:
NIAID
Licensee:
Fundação Butantan
Product:
Dengue fever vaccine

Dry eye, Neurotropic keratitis

Category:
Therapeutic
IC:
NIDCR
Licensee:
RegeneRX Biopharmaceuticals
Product:
RGN-259

Prostate cancer

Category:
Vaccine
IC:
NCI
Licensee:
BN Immunotherapeutics
Product:
PROSTVAC®